Poster #1 Phase 2 Study of Daratumumab+ CyBorD - Dose was split into two days to reduce infusion time - 101931

Spotlight
Video

Poster #1 Phase 2 Study of Daratumumab+ CyBorD - Dose was split into two days to reduce infusion time

ASHReport has 256 videos Subscribe Here

Loading........
Description: Robert Rifkin, MD from Rocky Mountain Cancer Center discusses poster #1 phase 2 study of Daratumumab+ CyBorD and the dose was split into two days to reduce infusion time at the 2017 American Society of Hematology.
Shared By : ASHReport
Posted on : 01/23/18
Added : 10 months ago
Category : Multiple Myeloma